Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06072040Phase 1Terminated

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia

Role: lead

NCT06078566Phase 1Terminated

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

Role: lead

NCT06225336Phase 1Terminated

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)

Role: lead

All 3 trials loaded